Moleculin Biotech to Present at Upcoming Investor

HOUSTON, TX --(Marketwired - June 01, 2017) - Moleculin Biotech, Inc., ( NASDAQ : MBRX ) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center ("MD Anderson"), today announced that Walter Klemp, Chairman and CEO, will present a corporate overview at the following investor conferences.

6 ^th Annual SeeThruEquity Microcap investor Conference Thursday, June 1 ^st at 10:30 am ET Convene Conference Center, New York, NY http://www.seethruequity.com/conference/

7 ^th Annual LD Micro Invitational Tuesday, June 6 ^th at 8:00 am PT Luxe Sunset Boulevard Hotel, Los Angeles, CA https://www.ldmicro.com/events

For more information about the conferences or to schedule a one-on-one meeting with Moleculin please contact Kirin Smith at ksmith@pcgadvisory.com .

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, an anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two preclinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors.

For more information about the Company, please visit http://www.moleculin.com .